ClinicalTrials.Veeva

Menu

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

U

University of Indonesia (UI)

Status and phase

Completed
Phase 2

Conditions

Diabetes Mellitus

Treatments

Drug: Insulin Glargine Pen Injector [Lantus]
Drug: Insulin Glargine Ezelin

Study type

Interventional

Funder types

Other

Identifiers

NCT03352674
IndonesiaU-01

Details and patient eligibility

About

This is an open-label randomised multicenter clinical study to compare immunogenicity of the drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes mellitus patients

Full description

Previous study has revealed that Insulin Glargine (Kalbe Farma) has similar efficacy with Lantus (Sanofi-Aventis) in controlling blood glucose in type 2 diabetes mellitus patients, but the immunogenicity potential of this product has not been known. Therefore, the present study is aiming to compare immunogenicity of Insulin Glargine (Kalbe Farma) and Lantus (Sanofi-Aventis) in type 2 diabetes mellitus patients in an open-label randomised multicenter clinical study.

Enrollment

133 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men or women, 18 years old and above
  • Diabetes mellitus type 2 patients who has failed an oral hypoglycemic drug products, insulin-naive, disease duration of at least 6 months, inadequate glycemic control (HbA1c > 7.0 %)
  • BMI ranged from 19 - 35 kg/m2
  • Consent from patients of childbearing potential to use contraception method throughout the study
  • Signed informed consent form

Exclusion criteria

  • History of diabetic ketoacidosis more than 2 times in the past 1 year
  • History of pancreatectomy
  • Estimated glomerular filtration rate <30 mL/min
  • Positive ZnT8 Antibody
  • Treatment with glucocorticoids, immunodepressant or cytostatics in 60 days before study.
  • Any malignant disease, including in medical history
  • Drugs and alcohol abuse, including in medical history
  • Hipersensitivity to insulin glargine or any excipient of the drugs from medical history
  • Mental disorders

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

133 participants in 2 patient groups

Insulin Glargine Ezelin
Experimental group
Description:
Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
Treatment:
Drug: Insulin Glargine Ezelin
Insulin Glargine Lantus
Active Comparator group
Description:
Insulin Glargine Pen Injector \[Lantus\]
Treatment:
Drug: Insulin Glargine Pen Injector [Lantus]

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems